News|Videos|February 24, 2023
Emerging Therapies in CLL
Dr Alexey Danilov explains data on emerging therapies, including anti-ROR1 therapies, BTK degrading agents, and bispecifics, for treatment of CLL.
Advertisement
Episodes in this series
Advertisement
Related to this article
Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
2
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
Acylfulvene Prodrug LP-184 Shows Tolerability in Recurrent Glioblastoma
5